AUG 04, 2015 11:57 PM PDT

Placebo Pills Help Insomnia

WRITTEN BY: Ilene Schneider
As few as half of the prescription sleeping pills are doing the job for about nine million Americans who use them for chronic insomnia, and placebos could work as part of their treatment plans, according to a new study published in the journal Sleep Medicine and reported in Futurity. These findings from the University of Pennsylvania (Penn) disagree sharply with the standard prescribing practices for chronic insomnia treatment (http://www.futurity.org/sleeping-pills-insomnia-975652/?utm_source=feedly&utm_medium=webfeeds).
Penn researchers show that placebo, in combination with sleep aids, helps insomnia.
The researchers advocate for a strategy that reduces sleep drugs and increases placebos, thereby decreasing the amount of medication needed to maintain medication effects over time. It would enable someone to maximize clinical gains in terms of falling and staying asleep while cutting down on side effects and prescription drug costs. Chronic insomnia is defined as "difficulty falling asleep or staying asleep at least three nights a week for at least one month."

According to the Sleep Foundation, there are many causes of insomnia: psychiatric and medical conditions, unhealthy sleep habits, specific substances and/or certain biological factors. Recent research has been exploring insomnia as a problem of the brain being unable to stop being awake. The brain has a sleep cycle and a wake cycle. If one cycle is turned on, the other is turned off. If there is too much wake drive or too little sleep drive, insomnia can be the result (http://sleepfoundation.org/insomnia/content/what-causes-insomnia).

According to the study's senior author, Michael Perlis, associate professor in the University of Pennsylvania's psychiatry department and director of the Penn Behavioral Sleep Medicine Program, "The clinical effects of sleeping pills cannot be relied on to last forever, and long-term use increases risk of psychological dependence and side effects including daytime drowsiness, nausea and muscle pain. Our research found that changing the industry standard for maintenance therapy can maintain treatment responses and lower the incidence of side effects."

The study gave 74 adults with chronic insomnia 10 mg of the sleeping pill zolpidem (Ambien) for four weeks. People who responded to the treatment were randomized into three dosing groups for 12 weeks: nightly dosing with 10 mg or 5 mg, intermittent dosing of 10 mg three to five days a week or partial reinforcement through nightly pills in which half were 10 mg capsules and half were placebo capsules. All three strategies helped people to fall and stay asleep, but those in the intermittent dosing group slept worse and reported more medical symptoms and greater symptom severity than those in the other dosing groups.

As Perlis explained, "When it comes to day-to-day quality of therapeutic outcomes, the strategy we use most frequently, the intermittent doing strategy performed worst. Our findings also go against the standard practice of ‘start low and go slow,' in favor of a ‘start high and go low' dosing strategy in which a patient starts with 10 mg nightly and then when the desired result is reached, switch to either a lower nightly dose or intermittent dosing with placebos on non-medication nights."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAR 01, 2020
Genetics & Genomics
MAR 01, 2020
Treating Huntington's Disease With a Gene Therapy That Targets Brain Cells
A new therapeutic approach for Huntington's disease may aid patients with other neurodegenerative disorders.
MAR 03, 2020
Neuroscience
MAR 03, 2020
How Brain is Wired Caused Learning Difficulties, Not Specific Brain Regions
For quite some time, science has attributed learning difficulties such as dyslexia and language processing disorder to m ...
MAR 30, 2020
Neuroscience
MAR 30, 2020
When is Stress Good for You?
Although stress has a pretty bad reputation- often touted as a major compounding factor for many diseases- some stress i ...
APR 11, 2020
Neuroscience
APR 11, 2020
Behavioral Changes Linked to Early Onset of Alzheimer's
Researchers from McGill University in Canada have found a link between mild behavioral impairment (MBI) in elderly indiv ...
APR 23, 2020
Cannabis Sciences
APR 23, 2020
No Difference Between Indica and Sativa Cannabis Strains
Cannabis growers and sellers have defined different strains of cannabis as ‘indica’ or ‘sativa’ ...
APR 27, 2020
Cell & Molecular Biology
APR 27, 2020
Cold Foods Don't Taste as Good, Even to Flies
The deliciousness of a food appeal is about a lot more than just taste.
Loading Comments...